Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.
Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.